VRTX
Vertex Pharmaceuticals Inc / Ma
$498.43
-23.82 (-4.56%)
At close · Jul 8
Market Cap
$126.50B
Shares
253,805,417
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$12B
+8.9%
FY2025
Net Income
$3.95B
+838.1%
FY2025
Gross Margin
86.24%
+0.1pp
FY2025
Operating Margin
34.77%
+36.9pp
FY2025
Diluted EPS
$15.32
+836.5%
FY2025
Operating Cash Flow
$3.63B
+837.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $12.95B – $13.1B | $12.22B | $12B | $11.02B | $9.87B | $8.93B | $7.57B | $6.21B | $4.16B | $3.05B | $2.49B | $1.7B | $1.03B | $580.42M | $1.21B | $1.53B | $1.41B | $143.37M | $101.89M | $175.5M | — | |
| — | -$43.1M | — | — | -$44.1M | -$54.8M | -$61.5M | -$58.2M | -$58.5M | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $1.68B | $1.65B | $1.53B | $1.26B | $1.08B | $904.2M | $736.3M | $547.8M | $409.54M | $275.12M | $210.46M | $117.15M | $39.73M | $88.98M | $236.74M | $63.63M | $0 | — | — | — | |
| — | $10.54B | $10.35B | $9.49B | $8.61B | $7.85B | $6.67B | $5.47B | $3.62B | $2.64B | $2.21B | $1.49B | $915.19M | $540.69M | $1.12B | $1.29B | $1.35B | $143.37M | — | — | — | |
| — | — | 86.24% | 86.11% | 87.21% | 87.9% | 88.06% | 88.14% | 86.84% | 86.56% | 88.95% | 87.64% | 88.65% | 93.16% | 92.66% | 84.5% | 95.49% | 100% | — | — | — | |
| — | $3.89B | $3.91B | $3.63B | $3.16B | $2.54B | $3.05B | $1.83B | $1.75B | $1.42B | $1.32B | $1.05B | $995.92M | $855.51M | $882.1M | $765.91M | $707.71M | $637.42M | $550.27M | $516.91M | — | |
| — | $1.85B | $1.75B | $1.46B | $1.14B | $944.7M | $840.1M | $770.5M | $658.5M | $557.62M | $496.08M | $432.83M | $376.58M | $305.41M | $356.19M | $432.68M | $400.72M | $187.8M | $130.19M | $101.29M | — | |
| — | — | $20.2M | $20.2M | $1.7M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $217.3M | $209.8M | $207.2M | $181.3M | $148.3M | $125.6M | $109.5M | $106.9M | $72.42M | $61.4M | $61.4M | $62.34M | $63.26M | $48.37M | $38.19M | $35.04M | $30.46M | $30.11M | $32.2M | — | |
| — | — | — | — | — | — | — | $0 | $0 | -$184K | $14.25M | $1.26M | $2.21M | $50.93M | $40.52M | $1.84M | $2.07M | $1.5M | $6.24M | $4.32M | $91.82M | |
| — | $7.54B | $7.83B | $11.25B | $6.04B | $4.62B | $4.79B | $3.35B | $2.97B | $2.41B | $2.37B | $1.69B | $1.5B | $1.27B | $1.82B | $1.48B | $1.3B | $839.45M | $715.9M | $638.21M | — | |
| — | $4.68B | $4.17B | -$232.9M | $3.83B | $4.31B | $2.78B | $2.86B | $1.2B | $635.15M | $123.24M | $9.94M | -$466.88M | -$692.41M | -$610.01M | $46.73M | $113.82M | -$696.08M | -$614.01M | -$462.71M | — | |
| — | — | 34.77% | -2.11% | 38.83% | 48.23% | 36.73% | 46.03% | 28.77% | 20.84% | 4.95% | 0.58% | -45.23% | -119.3% | -50.33% | 3.06% | 8.07% | -485.51% | -602.63% | -263.65% | — | |
| — | $4.9B | $4.38B | -$25.7M | $4.01B | $4.46B | $2.91B | $2.97B | $1.3B | $707.57M | $184.64M | $71.33M | -$404.54M | -$629.16M | -$561.64M | $84.92M | $148.86M | -$665.62M | -$583.91M | -$430.51M | — | |
| — | — | $13.3M | $30.6M | $44.1M | $54.8M | — | $58.15M | $58.5M | $72.47M | $69.3M | — | — | — | — | $16.65M | $38.45M | $19.28M | $13.19M | $13.47M | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $1.94M | $1.88M | $1.96M | $5.01M | $16.33M | — | |
| — | $9.9M | -$7.7M | -$86.1M | -$22.8M | -$164.8M | $4.9M | $296.6M | $192.2M | -$790K | -$81.38M | $4.13M | -$6.72M | $30.4M | $6.89M | $309K | -$15.69M | — | — | — | — | |
| — | $5.17B | $4.64B | $248.5M | $4.38B | $4.23B | $2.73B | $3.12B | $1.39B | $600.24M | -$15.69M | -$67.37M | -$557.8M | -$734.88M | -$626.04M | $32M | $60.45M | -$754.63M | -$642.18M | -$459.85M | — | |
| — | $827.4M | $690M | $784.1M | $760.2M | $910.4M | $388.3M | $405.2M | $218.1M | -$1.49B | -$107.32M | $16.67M | $30.38M | $6.96M | -$122.42M | -$275K | $19.27M | $0 | — | — | — | |
| — | $4.34B | $3.95B | -$535.6M | $3.62B | $3.32B | $2.34B | $2.71B | $1.18B | $2.1B | $263.48M | -$112.05M | -$556.33M | -$738.56M | -$445.03M | -$107.03M | $29.57M | -$754.63M | -$642.18M | -$459.85M | — | |
| — | — | 32.94% | -4.86% | 36.68% | 37.2% | 30.92% | 43.7% | 28.27% | 68.8% | 10.59% | -6.58% | -53.89% | -127.25% | -36.72% | -7.01% | 2.1% | -526.35% | -630.27% | -262.02% | — | |
| — | — | — | — | — | — | — | $0 | $0 | -$9.79M | -$171.85M | $28.02M | -$31.85M | — | -$242.52M | $55.9M | $11.61M | $0 | — | — | — | |
| — | — | — | — | — | — | — | $2.71B | $1.18B | $2.1B | $263.19M | -$112.05M | -$556.33M | -$737.64M | -$503.62M | $31.95M | $29.28M | -$754.63M | -$642.18M | — | — | |
| — | $4.3B | $3.81B | -$393.5M | $3.6B | $3.31B | $2.43B | $2.65B | $1.17B | $2.13B | $230.74M | -$92.7M | -$555.43M | -$737.33M | -$687.31M | -$50.63M | $29.59M | -$755.05M | — | — | — | |
| USD/shares | — | — | $15.46 | -$2.08 | $14.05 | $12.97 | $9.09 | $10.44 | $4.58 | $8.24 | $1.06 | -$0.46 | -$2.31 | -$3.14 | -$1.98 | -$0.50 | $0.14 | -$3.77 | -$3.71 | -$3.27 | — |
| USD/shares | — | — | $15.32 | -$2.08 | $13.89 | $12.82 | $9.01 | $10.29 | $4.51 | $8.09 | $1.04 | -$0.46 | -$2.31 | -$3.14 | -$1.98 | -$0.50 | $0.14 | -$3.77 | -$3.71 | -$3.27 | — |
| shares | — | — | 255.7M | 257.9M | 257.7M | 256.1M | 257.7M | 259.8M | 256.7M | 254.29M | 248.86M | 244.69M | 241.31M | 235.31M | 224.91M | 211.95M | 204.89M | 200.4M | 173.26M | 140.56M | — |
| shares | — | — | 258M | 257.9M | 260.5M | 259.1M | 259.9M | 263.4M | 260.7M | 259.19M | 253.23M | 244.69M | 241.31M | 235.31M | 224.91M | 215.26M | 208.81M | 200.4M | 173.26M | 140.56M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2016–FY2025: $6.12B in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
29.58×
Biotechnology median 7.60×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Pharmaceuticals | $12,001,300,000 | $11,020,100,000 | $9,869,200,000 | $8,930,700,000 |
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|
| United States | $7,548,600,000 | $6,684,900,000 | $6,040,400,000 | $5,699,300,000 | $4,829,282,000 | $3,062,555,000 | $2,365,079,000 | $1,986,786,000 |
| Outside the United States | $4,452,700,000 | $4,335,200,000 | $3,828,800,000 | $3,231,400,000 | $1,376,401,000 | $1,100,266,000 | $682,518,000 | $501,866,000 |
| Europe | $3,460,300,000 | $3,453,900,000 | $3,109,000,000 | $2,705,500,000 | $1,126,460,000 | $885,762,000 | $543,179,000 | $420,317,000 |
| Other Countries Outside of the United States and Europe | $992,400,000 | $881,300,000 | $719,800,000 | $525,900,000 | $249,941,000 | $214,504,000 | $139,339,000 | $81,549,000 |
By Product & Service (USD)
| Component | 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| ALYFTREK | $1,300,000,000 | $837,800,000 | $0 | $0 | — | — | — | — |
| Manufactured Product Other | — | $820,100,000 | $781,500,000 | $924,500,000 | $1,243,900,000 | — | — | — |
| Product | — | $11,970,600,000 | $11,020,100,000 | $9,869,200,000 | — | $7,573,400,000 | $6,202,800,000 | $4,160,700,000 |
| CASGEVY | — | $115,800,000 | $10,000,000 | — | — | — | — | — |
| Collaborativeand Royalty | — | $30,700,000 | $0 | $0 | — | $1,000,000 | $2,900,000 | $2,100,000 |
| JOURNAVX | — | $59,600,000 | — | — | — | — | — | — |
| Kalydeco | — | — | — | $475,500,000 | — | $684,200,000 | $802,900,000 | $991,000,000 |
| ORKAMBI | — | — | — | $326,000,000 | — | $771,600,000 | $907,500,000 | $1,331,900,000 |
| SYMDEKOSYMKEVI | — | — | — | $123,000,000 | — | $420,400,000 | $628,600,000 | $1,417,700,000 |
| TRIKAFTAKAFTRIO | — | $10,312,700,000 | $10,238,600,000 | $8,944,700,000 | $7,686,800,000 | $5,697,200,000 | $3,863,800,000 | $420,100,000 |
| TRIKAFTA | — | — | — | — | — | — | — | $420,105,000 |
Key facts
CIK
875320
CUSIP
92532F100
13F (30d)
102 filings
60 filers
Visit website
Investor relations